Peptide News Digest

AAIC 2026 Opens Sunday in London With Denali Ryan Watts Opening Plenary on Blood-Brain Barrier Biologic Delivery, Eisai/Biogen LEQEMBI Subcutaneous Autoinjector Data Supports SC-Comparable Efficacy and Safety, Voyager VY1706 Tau-Targeted BBB-Crossing AAV Gene Therapy Reduces Tau 64% in NHP Toxicology, Biogen Diranersen Phase 2 CELIA First Tau ASO to Show Pathology Reduction Plus Cognitive Benefit, Acumen Sabirnetug (ACU193) Amyloid-Beta Oligomer-Selective mAb Enhanced Brain Delivery Data, CNBC/Mercer Employer GLP-1 Coverage for Obesity Stuck at 36% Year-Over-Year

AAIC 2026 opens in London: Denali plenary on BBB delivery, LEQEMBI SC autoinjector data, Voyager tau AAV, Biogen diranersen, Acumen sabirnetug; CNBC employer coverage stuck at 36%.

6 stories · Covering clinical-trials, industry

Editor's Note

The Alzheimer's Association International Conference opened Sunday morning in London with Denali Therapeutics CEO Ryan Watts, PhD giving the opening plenary on delivering biologic therapies across the blood-brain barrier, a natural bridge from the Lonza-Nona TfR1 deal covered yesterday to a full clinical-stage program (AVLAYAH already approved for Hunter syndrome, DNL628 anti-tau ASO and DNL921 in early Alzheimer's development). Eisai and Biogen presented LEQEMBI subcutaneous autoinjector data showing efficacy and safety comparable to IV administration, supporting a fully SC treatment pathway from initiation through maintenance. Voyager Therapeutics disclosed GLP toxicology data for VY1706, a BBB-crossing AAV gene therapy targeting tau: 64% tau reduction in key brain regions of non-human primates at 13 weeks after a single IV dose, with FDA IND clearance and first-in-human Alzheimer's dosing expected H2 2026. Biogen also presented Phase 2 CELIA data for diranersen (BIIB080), the first tau-targeting ASO to show both pathology reduction and cognitive benefit. Acumen Pharmaceuticals will present Enhanced Brain Delivery data for sabirnetug (ACU193), the amyloid-beta oligomer-selective humanized mAb now in Phase 2 ALTITUDE-AD. On the metabolic side, CNBC's Healthy Returns and the Peterson Health Technology Institute documented that employer GLP-1 obesity coverage remains stuck at 36% year-over-year despite the July 1 Medicare Bridge launch: 27% of employers steer workers to direct-to-consumer cash platforms, 21% push FSA/HSA/HRA dollars, and the uninsured share for Zepbound rose 18% YoY.

Clinical Trials

Denali Therapeutics Co-Founder and CEO Ryan Watts, PhD Delivers the Opening Plenary at AAIC 2026 in London on Sunday July 12: 'Accelerating the Discovery and Development of Medicines for Neurodegeneration' — Blood-Brain Barrier Biologic Delivery Anchored on the TransportVehicle Platform, the March 2026 FDA-Approved AVLAYAH (Tividenofusp Alfa) for Hunter Syndrome, and Alzheimer's Investigational Programs DNL628 (Oligonucleotide TransportVehicle Targeting MAPT Tau) and DNL921

Denali Therapeutics (NASDAQ: DNLI) co-founder and CEO Ryan Watts, PhD delivered the opening plenary address at the Alzheimer's Association International Conference (AAIC) 2026 in London on Sunday July 12, 2026, titled 'Accelerating the Discovery and Development of Medicines for Neurodegeneration.' The presentation covered advances in neurodegeneration biology, biomarkers for diagnosis and treatment-effect assessment, and biologic therapies designed to cross the blood-brain barrier. Denali's proprietary TransportVehicle (TV) platform leverages the body's iron transport system (transferrin receptor) to shuttle antibodies, enzymes, and oligonucleotides into the brain. AVLAYAH (tividenofusp alfa-eknm) received FDA accelerated approval March 2026 as the first FDA-approved biologic specifically designed to cross the blood-brain barrier, for the treatment of neurologic manifestations of Hunter syndrome in certain pediatric patients. DNL628 is enabled by Denali's Oligonucleotide TransportVehicle (OTV) and targets the MAPT gene encoding tau, with data expected 1H 2027; DNL921 is a separate Alzheimer's candidate with Phase 1/2b data expected in 2027. The plenary framing ties to the Lonza-Nona Biosciences TfR1 blood-brain-barrier deal covered in Saturday's digest.

#denali-therapeutics #ryan-watts #aaic-2026 #opening-plenary #transportvehicle #avlayah #tividenofusp-alfa #dnl628 #dnl921 #blood-brain-barrier #hunter-syndrome #neurodegeneration
Clinical Trials

Eisai and Biogen Present LEQEMBI (Lecanemab) Subcutaneous Autoinjector Clinical Data at AAIC 2026 Sunday July 12 Developing Topics Session 'Lecanemab Subcutaneous Formulation in Early Alzheimer's Disease': Efficacy and Safety Comparable to Intravenous Administration Support a Fully Subcutaneous Treatment Pathway From Initiation Through Maintenance in Early Alzheimer's Disease, With Long-Term Use, Maintenance Dosing, and At-Home Administration Data

Eisai and Biogen announced Sunday July 12, 2026 that new clinical data presented at AAIC 2026 in London support that the LEQEMBI (lecanemab) subcutaneous autoinjector (SC-AI) formulation offers efficacy and safety comparable to intravenous (IV) administration in people with early Alzheimer's disease. Data were featured during the Developing Topics Session titled 'Lecanemab Subcutaneous Formulation in Early Alzheimer's Disease: Emerging Clinical Evidence and Practical Use Considerations,' covering the SC formulation, long-term use across diverse patient groups, maintenance dosing, and at-home administration. The findings support a fully subcutaneous treatment pathway from initiation through maintenance treatment, offering greater convenience and flexibility for patients and care partners. The FDA approved Eisai's Biologics License Application (BLA) for subcutaneous maintenance dosing with LEQEMBI IQLIK in August 2025; the SC autoinjector data at AAIC 2026 extends that framework to initial treatment and long-term dosing. Lecanemab is a humanized IgG1 monoclonal antibody selective for amyloid protofibrils; the July 12 dataset is peptide-adjacent to the broader biologic-CNS delivery coverage.

#eisai #biogen #leqembi #lecanemab #subcutaneous-autoinjector #aaic-2026 #alzheimers-disease #amyloid-protofibril #maintenance-dosing #at-home-administration
Clinical Trials

Voyager Therapeutics Presents VY1706 (Tau-Targeted Blood-Brain-Barrier-Crossing AAV Gene Therapy) Developing Topics Poster at AAIC 2026 (July 12-15 London): GLP Non-Human Primate Toxicology Study Data Show Single Intravenous Dose Well Tolerated Up to 5E13 vg/kg With Up to 64% Tau Reduction in Key Brain Regions at 13 Weeks; FDA IND Cleared, First-in-Human Alzheimer's Disease Clinical Trial Dosing Expected Second Half of 2026

Voyager Therapeutics (NASDAQ: VYGR) presented Developing Topics late-breaking poster data at AAIC 2026 in London (July 12-15) featuring VY1706, its investigational blood-brain-barrier-crossing AAV gene therapy targeting intracellular and extracellular tau for Alzheimer's disease. The 3-month GLP non-human primate toxicology study showed VY1706 was well tolerated at a single intravenous dose up to the highest level tested (5E13 vg/kg), with no adverse clinical pathology or histopathological findings. Tau protein was reduced up to 64% in key brain regions of non-human primates at 13 weeks following a single IV dose. Voyager received FDA Investigational New Drug (IND) clearance for VY1706 in H1 2026, enabling initiation of a clinical trial in adults with early Alzheimer's disease with dosing expected in the second half of 2026. The program extends the same BBB-delivery-plus-tau-reduction thesis that Denali's DNL628 OTV pursues via anti-tau ASO; both address the same therapeutic hypothesis through different modalities (AAV gene therapy vs. anti-sense oligonucleotide).

#voyager-therapeutics #vygr #vy1706 #tau #aav-gene-therapy #blood-brain-barrier #aaic-2026 #alzheimers-disease #ind-clearance #nhp-toxicology
Clinical Trials

Biogen Presents Phase 2 CELIA Data for Diranersen (BIIB080) at AAIC 2026 Tuesday July 14 Developing Topics in Phase 2 Clinical Trials Session: 18-Month Study in Early Alzheimer's Disease Is the First Tau-Targeting Antisense Oligonucleotide (ASO) to Show Both Reduction in Tau Pathology and Cognitive Benefit, Building on May 2026 Topline Announcement; Program Now Advances Toward Phase 3 Development With Clinical, Biomarker, and Safety Data Characterizing the Investigational Molecule

Biogen (NASDAQ: BIIB) will present Phase 2 CELIA study data for diranersen (BIIB080), an investigational tau-targeting antisense oligonucleotide (ASO), at AAIC 2026 in London during the Developing Topics in Phase 2 Clinical Trials session on Tuesday July 14, 2:00–3:30 PM BST. The 18-month CELIA study evaluated diranersen in patients with early Alzheimer's disease and is the first study to show reduction in tau pathology and cognitive benefit for a tau-targeted therapy. Biogen will present clinical, biomarker, and safety data that build on the May 2026 topline announcement and further characterize the molecule as the program advances toward Phase 3 development. Diranersen targets MAPT RNA to reduce tau production at its source, a differentiated approach to addressing abnormal tau both inside and outside neurons. The CELIA readout is a peptide-adjacent nucleic-acid biologic milestone that shifts the tau treatment conversation from 'reducing pathology' to 'reducing pathology and moving cognition.'

#biogen #diranersen #biib080 #tau #antisense-oligonucleotide #aso #celia #phase-2 #aaic-2026 #alzheimers-disease #cognitive-benefit
Clinical Trials

Acumen Pharmaceuticals (NASDAQ: ABOS) Presents Data on Enhanced Brain Delivery (EBD) Technology and Early Alzheimer's Disease Insights for Sabirnetug (ACU193) at AAIC 2026 in London (July 12-15): Humanized Monoclonal Antibody Selective for Toxic Soluble Amyloid-Beta Oligomers (AβOs) Relative to Aβ Monomers and Amyloid Plaques, With Phase 2 ALTITUDE-AD Trial Ongoing in Early Symptomatic AD and Topline Results Expected Late 2026 Following Positive Phase 1 INTERCEPT-AD Results

Acumen Pharmaceuticals (NASDAQ: ABOS) will present data on its Enhanced Brain Delivery (EBD) technology and early Alzheimer's disease insights for sabirnetug (ACU193) at AAIC 2026 in London (July 12-15, both in-person and online). Sabirnetug is a humanized monoclonal antibody discovered and developed based on its selectivity for soluble amyloid-beta oligomers (AβOs, a highly toxic and pathogenic form of Aβ) relative to Aβ monomers and amyloid plaques. Soluble AβOs bind to neurons, inhibit synaptic function, and induce neurodegeneration; the mechanism differentiates sabirnetug from plaque-directed anti-amyloid antibodies (lecanemab, donanemab) that clear fibrillar Aβ. Acumen advances sabirnetug in the ongoing Phase 2 ALTITUDE-AD trial in early symptomatic AD, following positive Phase 1 INTERCEPT-AD results. Topline ALTITUDE-AD results are expected in late 2026. The Enhanced Brain Delivery technology component further connects to the day's broader BBB-delivery theme anchored on Denali's opening plenary and the Lonza-Nona deal.

#acumen-pharmaceuticals #abos #sabirnetug #acu193 #amyloid-beta-oligomer #enhanced-brain-delivery #aaic-2026 #altitude-ad #intercept-ad #alzheimers-disease #monoclonal-antibody
Industry

CNBC Healthy Returns (July 8): Employer GLP-1 Coverage for Obesity Held Steady at 36% Year-Over-Year Despite Medicare GLP-1 Bridge Launch on July 1 — 60% of Employers Cover GLP-1s for Diabetes Only, 3% Don't Cover, 2% Unsure; 27% of Employers Steer Workers to Direct-to-Consumer Cash Platforms, 21% Push FSA/HSA/HRA Spending; Uninsured Share for Zepbound Rose 18% Year-Over-Year, Leaving 114 Million Americans With No Commercial Coverage for the Drug

CNBC Healthy Returns and the Peterson Health Technology Institute (PHTI) documented Wednesday July 8, 2026 that employer coverage of GLP-1 drugs for obesity has held steady at 36% year-over-year despite the Medicare GLP-1 Bridge launching on July 1 and putting downward pressure on the payer landscape. Mercer survey data shows 60% of employers cover GLP-1s for diabetes only, 36% cover for both diabetes and weight loss, 3% don't cover them at all, and 2% are not sure. Rather than expanding coverage, employers pursued alternative approaches: 27% steer workers to direct-to-consumer cash platforms (such as LillyDirect, NovoCare Pharmacy, and telehealth intermediaries), while 21% push workers to use FSA, HSA, or integrated HRA dollars. GoodRx data show the uninsured share for Zepbound rose 18% year-over-year, leaving over 114 million Americans with no commercial coverage for the drug; 88% of those who do have coverage face additional requirements like prior authorization. GLP-1 drugs accounted for 11.4% of annual claims for employers covering them in 2026, up from 6.9% in 2023, sustaining the affordability tension that has kept coverage stuck.

#cnbc #employer-coverage #glp-1 #obesity #mercer #phti #medicare-glp1-bridge #goodrx #zepbound #wegovy #dtc-platforms #prior-authorization